Loading...
Organogenesis Q1 2025 Earnings Report
Organogenesis Holdings Inc. reported a significant decrease in net revenue and a substantial increase in net loss for the first quarter of 2025 compared to the same period in 2024.
Key Takeaways
Organogenesis Holdings Inc. reported a net revenue of $86.7 million for the first quarter of 2025, a 21% decrease from $110.0 million in the prior year. The company experienced a net loss of $18.8 million, a significant increase from a net loss of $2.1 million in the first quarter of 2024. This decline was primarily driven by a 23% decrease in Advanced Wound Care product revenue.
Net revenue for Q1 2025 was $86.7 million, a 21% decrease from $110.0 million in Q1 2024.
Net loss for Q1 2025 was $18.8 million, an increase of $16.7 million from a net loss of $2.1 million in Q1 2024.
Advanced Wound Care product revenue decreased by 23% to $79.9 million, while Surgical & Sports Medicine product revenue increased by 11% to $6.8 million.
Adjusted EBITDA loss was $12.5 million for Q1 2025, a decrease of $15.1 million from an Adjusted EBITDA income of $2.6 million in Q1 2024.
Revenue by Segment
Forward Guidance
For the year ending December 31, 2025, Organogenesis Holdings Inc. reaffirms its prior revenue guidance and updates its profitability guidance.
Positive Outlook
- Net revenue is projected to be between $480.0 million and $535.0 million, representing a year-over-year change in the range of roughly flat to an increase of 11%.
- Net revenue from Advanced Wound Care products is expected to be between $450.0 million and $500.0 million, a decrease of 1% to an increase of 10% year-over-year.
- Net revenue from Surgical & Sports Medicine products is expected to be between $30.0 million and $35.0 million, an increase of 6% to 23% year-over-year.
- Net income is projected to be between $4.7 million and $34.0 million.
- Adjusted net income is projected to be between $15.3 million and $44.6 million.
Challenges Ahead
- The guidance for Advanced Wound Care products includes a potential decrease of 1% year-over-year.
- The company acknowledges a challenging market and evolving reimbursement landscape.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...